FDA Accepts Dyne Therapeutics' BLA for Zeleciment Rostudirsen in DMD, Sets January 21, 2027 PDUFA Date

The FDA accepted Dyne Therapeutics' Biologics License Application for zeleciment rostudirsen on July 20, 2026, assigning a PDUFA target action date of January 21, 2027 — a hard deadline that now anchors the company's stated plan to launch in the first quarter of 2027, subject to approval.

The application covers z-rostudirsen (also designated DYNE-251) for Duchenne muscular dystrophy amenable to exon 51 skipping, which represents approximately 13% of the overall DMD patient population, per the company's July 20, 2026 news release on GlobeNewswire. The FDA granted Priority Review, with accelerated approval premised on dystrophin expression as a surrogate endpoint — the same mechanistic basis on which Sarepta Therapeutics' Exondys 51 was cleared nine years ago. Avidity is preparing to file a BLA for its own exon-skipper, del-zota, and Solid Biosciences is in Phase 1/2 studies with gene therapy SGT-003, per sourced competitive reporting.

The molecule is structurally distinct from currently approved exon 51 skippers. It is a phosphorodiamidate morpholino oligomer conjugated to a transferrin receptor 1-targeting antibody fragment, designed to drive near-full length dystrophin production in both muscle and the central nervous system via monthly IV dosing — not the weekly regimen required by currently approved exon 51-skipping therapies, per the July 20, 2026 Dyne news release.

The registrational expansion cohort of Dyne's global Phase 1/2 DELIVER trial comprised 32 patients — 24 on therapy at 20 mg/kg every four weeks and eight on placebo — and met its primary endpoint of statistically significant change from baseline in muscle-content adjusted dystrophin expression. That dataset is the backbone of the BLA. Separately, a December readout from the Phase 1/2 program drew a notable external assessment: Stifel analysts characterized the functional improvements as the "best ever" for an exon-skipper in DMD, per FierceBiotech reporting from December 2025.

Z-rostudirsen carries Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the FDA, plus Orphan Drug designation from the FDA, the EMA, and Japan's Ministry of Health, Labour and Welfare, per the company's July 20, 2026 news release.

Dyne moved immediately to fund the commercial runway. On July 21, 2026, per the company's GlobeNewswire release, it priced an upsized underwritten public offering of 18,300,000 shares at $20.50 per share, with gross proceeds expected to reach $375,150,000. Underwriters hold a 30-day option on an additional 2,745,000 shares. The offering was expected to close on or about July 23, 2026. The last reported sale price on July 20, 2026 was $23.45 per share, per Morningstar. Dyne intends to use the proceeds alongside existing cash and a recently drawn $50.0 million term loan from Hercules to fund clinical development, regulatory work, manufacturing, commercial build-out, and pipeline R&D, per the July 21, 2026 offering announcement.

As of the July 20, 2026 close, shares outstanding were 165.31 million, with a reported market cap of $3.88 billion and a 52-week range of $8.88 to $25.00, per Morningstar.

The competitive picture is shifting quickly. Sarepta's exon-skipping portfolio — Exondys 51, Vyondys 53, and Amondys 45 — has held the DMD exon-skipping space since 2016. Avidity is preparing to file a BLA for its own exon-skipper, del-zota. Solid Biosciences is pursuing a different approach entirely, with its gene therapy SGT-003 in Phase 1/2 studies. The exon 51-amenable population Dyne is targeting is the same one Exondys 51 was built around.

Beyond z-rostudirsen, Dyne is advancing four additional development candidates: DYNE-253 for exon 53 skipping, DYNE-245 for exon 45, DYNE-244 for exon 44, and DYNE-255 for exon 55, per the company's July 20, 2026 news release.

What is actually next: the FDA has until January 21, 2027 to act on the BLA. Dyne's stated commercial plan is a U.S. launch in the first quarter of 2027, contingent on that approval.